Bio-Rad Laboratories has secured approval from the US Food and Drug Administration (FDA) for its BioPlex 2200 Lyme Total assay. The BioPlex 2200 Lyme Total assay is an advanced multiplex test method, which will be used in the diagnosis of Lyme disease. Lyme disease is the common tick-borne illness in the US, and most of its signs and symptoms are similar to other conditions, which makes diagnosis complicated. BioPlex 2200 Lyme Total assay holds capacity to simultaneously detect multiple targets, enabling laboratories to collect valuable information in the early stages of Lyme disease to facilitate quick treatment for patients. BioPlex 2200 Lyme Total assay is the latest product in Bio-Rad’s infectious disease menu for the BioPlex 2200 system, which is an automated multiplex technology platform. The BioPlex 2200 system allows clinical laboratories to rapidly process or multiplex multiple individual tests that are traditionally processed separately.